Published in Vaccine Weekly, December 10th, 2008
Protea is developing an innovative next-generation vaccine against diseases caused by Streptococcus pneumoniae, based on widely conserved pneumococcal proteins. Pneumococcal vaccine is one of the two largest market segments in prophylactic vaccines. Sales of $2.5B for pneumococcal vaccines in 2007 are growing at an annual rate of >30%.
Zvika Rubenstein, CEO of the Meytav Technological Incubator (Meytav),...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly